Metraipolis › archive › dc_ffe72bf4b185
Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system — Europe PMC PMID:38724914
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/38724914
- DOI
- 10.1186/s12879-[numero omesso]-4
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T14:30:08.255Z
- SHA-256 of the archived text
df5994a49d36932b0730ef1c521594ffd343887e7f7245e6cb4bba34df50d9d7- Stable URL of this page
https://metraipolis.com/documento/dc_ffe72bf4b185
How to cite
Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system — Europe PMC PMID:38724914 — Europe PMC (en), https://europepmc.org/article/MED/38724914 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ffe72bf4b185 (Metraipolis archive dc_ffe72bf4b185, sha256 df5994a49d36932b0730ef1c521594ffd343887e7f7245e6cb4bba34df50d9d7)
BibTeX
@misc{dcffe72bf4b185,
title = {Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system — Europe PMC PMID:38724914},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/38724914},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ffe72bf4b185; sha256 df5994a49d36932b0730ef1c521594ffd343887e7f7245e6cb4bba34df50d9d7},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/38724914. Agents can read the archived copy with the MCP tool read_document.